We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Zinc on Barrett's Metaplasia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2013 by James M. Mullin, Ph.D., Main Line Health.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01984580
First Posted: November 14, 2013
Last Update Posted: November 14, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Sharpe-Strumia Research Foundation
Information provided by (Responsible Party):
James M. Mullin, Ph.D., Main Line Health
  Purpose

Using orally administered zinc to patients already diagnosed with the pre-cancerous condition, Barrett's Esophagus, this study is asking two questions:

  1. can this zinc administration cause molecular-level changes in the Barrett's tissue?
  2. are the changes measured indicative of chemopreventive action by zinc regarding cancer progression?

Condition Intervention Phase
Barrett's Metaplasia Drug: zinc gluconate Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Effect of Zinc on Barrett's Metaplasia

Resource links provided by NLM:


Further study details as provided by James M. Mullin, Ph.D., Main Line Health:

Primary Outcome Measures:
  • Changes in zinc-regulated cellular proteins within Barrett's tissue [ Time Frame: in biopsy tissue after 14 days of Zn exposure ]

Secondary Outcome Measures:
  • Changes in cellular microRNA profile; changes in protein cancer biomarkers [ Time Frame: in biopsy tissue after 14 days of Zn exposure ]

Estimated Enrollment: 120
Study Start Date: April 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Zinc Drug: zinc gluconate
26.6 mg zinc BID (as zinc gluconate)
Placebo Comparator: sodium

Detailed Description:
14 days prior to already-scheduled upper endoscopy (EGD) procedures for routine surveillance of Barrett's tissue, patients who have given written, informed consent are randomized (sealed envelope method) and placed on an oral dose of zinc gluconate (26.6 mg zinc BID) or a placebo (molar equivalent of sodium gluconate BID) for 14 days. At the time of endoscopy, 4 biopsies are taken (and pooled) from the Barrett's tissue and 4 from proximal normal esophageal tissue. Biopsies are flash frozen for later analyses by atomic absorption spectroscopy, PAGE and Western immunoblot or RNA microarray.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:ages 18-80; prior diagnosis of Barrett's esophagus -

Exclusion Criteria:unable to provide written, informed consent; prior history of Barrett's dysplasia or esophageal adenocarcinoma; drug exclusions: hormone replacement therapy, cholestyramine, amiloride diuretics, oral quinolone antibiotics, glucocorticoids, corticosteroids, anticoagulants (other than aspirin)

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01984580


Contacts
Contact: James M Mullin, Ph.D. 484-476-2708 mullinj@mlhs.org

Locations
United States, Pennsylvania
Lankenau Institute for Medical Research Recruiting
Wynnewood, Pennsylvania, United States, 19096
Sponsors and Collaborators
Main Line Health
Sharpe-Strumia Research Foundation
  More Information

Responsible Party: James M. Mullin, Ph.D., Professor, Main Line Health
ClinicalTrials.gov Identifier: NCT01984580     History of Changes
Other Study ID Numbers: F/N-R-11-3038L
First Submitted: November 8, 2013
First Posted: November 14, 2013
Last Update Posted: November 14, 2013
Last Verified: November 2013

Keywords provided by James M. Mullin, Ph.D., Main Line Health:
Barrett's esophagus
Esophagus
Adenocarcinoma

Additional relevant MeSH terms:
Barrett Esophagus
Metaplasia
Pathologic Processes
Digestive System Abnormalities
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Zinc
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs